Pfizer’s ZAVZPRET™ (zavegepant) Migraine Nasal Spray Receives FDA Approval

Go back to Pfizer’s ZAVZPRET™ (zavegepant) Migraine Nasal Spray Receives FDA Approval

FDA approves Pfizer's (PFE) migraine nasal spray

March 10, 2023 11:44 AM EST

Pfizer (NYSE: PFE) shares edged higher despite the overall dip in equities in the early part of Friday's session after it announced the U.S. Food and Drug Administration (FDA) has approved its migraine nasal spray.

ZAVZPRET was shown to be "statistically... More